Report: Payers may want more biosimilar data

Payers may be more demanding about biosimilars data than regulators prove to be, a report from Decision Resources says. Apparently, payers are questioning whether the FDA's requirements will answer all of their questions about bioequivalence of branded biotech meds and other companies' copycat versions. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.